A chiral bisphosphine ligand and its rhodium complex and preparation method and application thereof
By developing complex catalysts of chiral bisphosphine ligands and rhodium salts, the problems of low efficiency and poor stability of existing catalysts are solved, and the efficient asymmetric hydrogenation of β-dehydrogenated amino acid esters are achieved, providing solutions for industrial synthesis .
Patent Information
- Application Number
- CN202210080600.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-01-24
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-01-24
Smart Images

Figure BDA0003485713310000021 
Figure BDA0003485713310000022 
Figure BDA0003485713310000031
Abstract
Description
Technical Field
[0001] The invention relates to a chiral bisphosphine ligand and a rhodium complex thereof, a preparation method of the chiral bisphosphine ligand and the rhodium complex thereof, and application of the rhodium complex as a catalyst in the asymmetric catalytic hydrogenation reaction of beta-dehydrogenated amino acid esters. Background Art
[0002] Chiral β-amino acids and their derivatives are an important class of molecules, and their fragments exist in many drug molecules (such as the anti-HIV drug dolutegravir and the hypoglycemic drug emirezide) [(1) Juaristi, E.; Quintana, D.; Escalante, J. Aldrichimica Acta 1994, 27, 3. (2) Nicolaou, KC; Dai, WM; Guy, RK Angew. Chem. Int. Ed. Engl. 1994, 33, 15. (3) Hughes, DLOg. Process Res. Dev. 2019, 23, 716]. Therefore, the efficient asymmetric synthesis of chiral β-amino acids and their derivatives has attracted widespread attention [Cardillo, G.; Tomasini, C. Chem. Soc. Rev. 1996, 25, 117].
[0003] The asymmetric catalytic hydrogenation of β-dehydroamino acid esters has the advantages of easy availability of raw materials, simple operation, high atomic utilization, and clean process. It is an effective method for preparing optically active β-amino acid ester derivatives. The development of efficient and highly selective chiral catalysts is the key to the practical application of this reaction.
[0004] Over the past four decades, great progress has been made in the research on the asymmetric catalytic hydrogenation of β-dehydroamino acid esters. A variety of metal complex catalysts modified with monophosphine ligands or diphosphine ligands have been developed for this reaction, some of which have achieved high enantioselectivity. However, the reported catalysts are usually not efficient (the catalyst dosage is usually 1 mol%), and there are also problems such as complex ligand structure, difficult synthesis, poor stability, and the use of solvents that are not suitable for industrial production, which limit their industrial application [(1) Tang, W.; Zhang, X. Chem. Rev. 2003, 103, 3029. (2) Xie, J.-H. Zhu, S.-F.; Zhou, Q.-L. Chem. Rev. 2011, 111, 1713. Ager, DJ; de Vries. AHM; de Vries. JG Chem. Soc. Rev. 2012, 41, 3340]. Summary of the invention
[0005] The present invention aims to provide a novel chiral bisphosphine ligand and a rhodium complex catalyst thereof, as well as a preparation method and use thereof. The rhodium complex catalyst of the present invention exhibits excellent catalytic activity and high enantioselectivity, provides a synthesis method suitable for industrialization for optically active β-amino acids and their derivatives, and has good application prospects.
[0006] Specifically, the present invention provides a chiral bisphosphine ligand of the present invention shown in the following general formula I, wherein the chiral bisphosphine ligand is prepared from optically pure 1-phenylethylamine, and two aryl phosphine substituents are introduced into the ortho positions of the amino group and the phenyl group respectively through reactions such as lithiation and substitution, and the chiral bisphosphine ligand is further complexed with a rhodium salt to generate a corresponding rhodium complex. The rhodium complex can be used as a catalyst for asymmetric hydrogenation of β-dehydrogenated amino acid esters.
[0007] The novel chiral diphosphine ligand of the present invention has the following structural formula I:
[0008]
[0009] Where: R 1 is an alkyl group; R 2 It is an aryl group or a substituted aryl group.
[0010] The alkyl group mentioned above refers to a straight chain or branched chain alkyl group having 1 to 24 carbon atoms, for example: methyl, ethyl, benzyl, cyclohexyl, n-butyl, n-tridecyl, adamantyl, etc. Preferably, a straight chain or branched chain alkyl group has 1 to 13 carbon atoms, particularly preferably a straight chain or branched chain alkyl group has 1 to 7 carbon atoms, and most preferably a methyl, ethyl, benzyl group.
[0011] The aryl or substituted aryl mentioned above refers to an aryl or substituted aryl having 1 to 24 carbon atoms. For example: phenyl, naphthyl, 4-methoxyphenyl, 3,5-dimethylphenyl, 4-methylphenyl, 3,5-di-tert-butylphenyl, 2-methylphenyl, 4-tert-butylphenyl, etc. Phenyl or substituted phenyl having 1 to 24 carbon atoms is preferred, substituted phenyl having 8 to 24 carbon atoms is particularly preferred, and 4-methoxyphenyl, 3,5-dimethylphenyl, 3,5-di-tert-butylphenyl is most preferred.
[0012] As a preference, R 1 is methyl, ethyl, benzyl, R 2 It is 4-methoxyphenyl, 3,5-dimethylphenyl, and 3,5-di-tert-butylphenyl.
[0013] The preferred chiral bisphosphine ligand I of the present invention has the following structure.
[0014]
[0015] The present invention also provides a method for preparing the chiral diphosphine ligand I, which is prepared by the following steps:
[0016] (1) In a first solvent, at -35°C, (S)-1-phenylethylamine reacts with n-butyl lithium and trimethylsilyl chloride to undergo ortho-lithiation, and then reacts with disubstituted phosphorus chloride to prepare an ortho-phosphine-substituted intermediate II, the reaction formula of which is:
[0017]
[0018] The first solvent in step (1) is one or a mixture of two or more of diethyl ether, tetrahydrofuran, methyl tert-butyl ether and toluene.
[0019] The molar ratio of (S)-1-phenylethylamine, n-butyl lithium, trimethylsilyl chloride and disubstituted phosphorus chloride is 1:2-8:1-3:1-4.
[0020] (2) In a second solvent, at 0-60° C., the ortho-phosphine-substituted intermediate II undergoes a reductive amination reaction with an aldehyde and sodium borohydride to prepare a secondary amine intermediate III, wherein the reaction formula is:
[0021]
[0022] The second solvent in step (2) is one or a mixture of two or more of methanol, ethanol, toluene, tetrahydrofuran and dichloromethane.
[0023] R in the reaction formula of step (2) 3 R 1 An alkane with one less carbon atom.
[0024] (3) In a solvent at 0-120° C., using triethylamine as a base, the secondary amine intermediate III is reacted with diphenylphosphine chloride to prepare a chiral bisphosphine ligand I, wherein the reaction formula is:
[0025]
[0026] Among them, R 1 -R 2 As defined above.
[0027] The third solvent in step (3) is one or a mixture of two or more of dichloromethane, toluene and tetrahydrofuran.
[0028] The present invention also provides a chiral diphosphine ligand rhodium complex IV, which has the following structural formula:
[0029]
[0030] Among them, R 1-R 2 As defined above.
[0031] X - They are: chloride ion, tetrafluoroborate ion, hexafluorophosphate ion, hexafluoroantimonate ion, trifluoromethanesulfonate ion, tetrakis(3,5-ditrifluoromethylphenyl)boron anion.
[0032] Chiral diphosphine ligand rhodium complex IV can be prepared by the following two methods:
[0033] Such as X - The preparation method is that the chiral bisphosphine ligand is complexed with rhodium salt and silver salt of corresponding anion in a solvent at 20-30° C. for 2-4 hours to prepare a chiral bisphosphine ligand rhodium complex containing different anions, and the reaction formula is:
[0034]
[0035] Such as X - It is tetrakis(3,5-ditrifluoromethylphenyl)borane anion, and the preparation method is that in a solvent, at 20-30°C, a chiral bisphosphine ligand, a corresponding rhodium salt and NaBAr F Complexation for 2-4 hours to prepare BAr F -anionic chiral diphosphine ligand rhodium complex, the reaction formula is:
[0036]
[0037] in:
[0038] R 1 -R 2 As defined above
[0039] Y is 1,5-cyclooctadiene.
[0040] The solvents described in the two methods are: one or a mixture of two or more of dichloromethane, benzene, toluene, xylene, ether, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, and isopropanol.
[0041] The present invention also provides the application of chiral diphosphine ligand rhodium complex IV, which is used as a catalyst for asymmetric catalytic hydrogenation of β-dehydrogenated amino acid esters. The reaction equation is as follows:
[0042]
[0043] in:
[0044] R x is alkyl, phenyl, substituted phenyl, heteroaryl, or substituted heteroaryl;
[0045] R y is alkyl, phenyl, substituted phenyl, heteroaryl, or substituted heteroaryl;
[0046] R z is alkyl, phenyl, substituted phenyl, heteroaryl, or substituted heteroaryl;
[0047] The double bonds in the raw materials are in Z-configuration, E-configuration or a mixture of the two.
[0048] The R mentioned above x ,R y ,R z It refers to an alkyl group, phenyl group, substituted phenyl group, heteroaryl group, substituted heteroaryl group having 1 to 24 carbon atoms. For example, methyl group, ethyl group, cyclohexyl group, n-butyl group, phenyl group, 4-methylphenyl group, pyridyl group, 4-methylpyridyl group, etc. Preferably, it is an alkyl group or aryl group having 1 to 13 carbon atoms, and particularly preferably, it is an alkyl group having 1 to 7 carbon atoms. Most preferably, R x is methyl, R y is methyl, ethyl, isopropyl or phenyl, R z It is ethyl.
[0049] Application of chiral bisphosphine ligand rhodium complex IV: Under argon atmosphere, reactants, catalysts, and degassed solvents are added into a hydrogenation inner tube in sequence, and then stirred at room temperature under hydrogen atmosphere until the reaction is completed.
[0050] The application of the chiral bisphosphine ligand rhodium complex IV and the asymmetric catalytic hydrogenation reaction conditions are: the solvent used is one or more organic solvents selected from benzene, toluene, xylene, ether, methyl tert-butyl ether, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, isopropanol and tert-butanol; the amount of the catalyst is 0.01-10 mol%; the hydrogen pressure is 1 atm-100 atm; the substrate concentration is 0.001-10.0 M; the reaction temperature is 0-100°C; and the reaction time is 1-72 hours.
[0051] The preferred amount of catalyst used is 0.1-1 mol%, and the more preferred amount of catalyst used is 1 mol%.
[0052] The preferred hydrogen pressure is 10 atm-60 atm, and the more preferred hydrogen pressure is 30 atm.
[0053] The preferred substrate concentration is 0.01-1.0M, and the more preferred substrate concentration is 0.1M.
[0054] The preferred reaction temperature is 20-100°C, and the more preferred reaction temperature is 25°C.
[0055] The preferred reaction time is 12-48 hours, and the more preferred reaction time is 12 hours.
[0056] Advantages and beneficial effects of the present invention:
[0057] The chiral bisphosphine ligand provided by the present invention has a simple preparation process and cheap and readily available raw materials; the chiral bisphosphine ligand is complexed with a rhodium salt to prepare a corresponding chiral bisphosphine ligand rhodium complex, and the complex is used as a catalyst with a clear structure and high stability. The asymmetric hydrogenation of various beta-dehydrogenated amino acid esters is achieved, and the conversion number can reach 1900 (the ratio of the amount of the target product to the amount of the catalyst), and the enantioselectivity is 91%ee. The novel chiral bisphosphine ligand rhodium complex catalyst provided by the present invention is one of the most efficient rhodium catalysts for asymmetric hydrogenation of beta-dehydrogenated amino acid esters, and has good application prospects. DETAILED DESCRIPTION
[0058] The following embodiments will help to further understand the present invention, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments. All technologies realized based on the above content of the present invention belong to the scope of the present invention.
[0059] General Notes:
[0060] The abbreviations used in the following examples have the following meanings:
[0061] Me is methyl, Et is ethyl, i Pr is isopropyl, t Bu is tert-butyl, Ph is phenyl, Bn is benzyl, COD is 1,5-cyclooctadiene, OTf is triflate, MeOH is methanol, EtOH is ethanol, THF is tetrahydrofuran, DCM is dichloromethane, PE is petroleum ether, EA is ethyl acetate, toluene is toluene, MTBE is methyl tert-butyl ether, Ar is argon, and rt refers to room temperature.
[0062] eq is equivalent, S / C is the molar ratio of substrate to catalyst, TLC is thin layer chromatography, NMR is nuclear magnetic resonance, and HRMS is high resolution mass spectrometry.
[0063] The solvents used were purified, degassed and dried by standard operations before use; the reagents used were commercially available or synthesized according to existing literature methods and purified before use.
[0064] Example 1: Preparation of Intermediates (S)-1-(2-diarylphosphino)phenylethylamine IIa-IIc
[0065] (S)-1-(2-Bis(3,5-dimethylphenyl)phosphine)phenylethylamine(IIa)
[0066]
[0067] Place a 250mL three-necked flask under argon protection, then add super dry ether (50mL) and (S)-1-phenylethylamine (3.82mL, 30mmol), stir the system evenly and pre-cool it at -35℃. Under stirring conditions, add n-butyl lithium (12mL, 30mmol, 2.5M in THF) dropwise to the system. After the addition is complete, stir at -35℃ for 30min. Then, trimethylsilyl chloride (4.26 mL, 30 mmol) was added dropwise to the system at -35 °C with stirring, and the mixture was stirred at -35 °C for 1.5 h. Then, n-butyl lithium (36 mL, 90 mmol, 2.5 M in THF) was added dropwise to the system at -35 °C with stirring, and the mixture was warmed to room temperature within 2 h and stirred overnight. Then, di(3,5-dimethylphenyl)phosphine chloride in ether solution (12.45 g, 45 mmol in 30 mL) was slowly added dropwise to the reaction system at -35 °C with stirring. Et2O), add dropwise, and stir at -35°C for 4h. Then warm the system to room temperature and react for 8h. Monitor the reaction by TLC. After the reaction is completed, add 1M hydrochloric acid to the system at 0°C with stirring until the two phases are clear. Use a separatory funnel to separate the liquids. Extract the aqueous phase with MTBE (100mL×3), combine the organic phases, wash the organic phases with saturated brine, and then dry with anhydrous magnesium sulfate. Filter, concentrate the filtrate by rotary evaporation, and separate the crude product by silica gel column chromatography (eluent: dichloromethane / methanol=20:1, v / v). Finally, 3.35g of compound IIa is obtained as a yellow solid. The total yield of the three-step reaction is 31%, [α] D 26 =41.7 (c 0.50, CHCl3), melting point 92-95°C.
[0068] 1 H NMR (400MHz, CDCl3) δ7.63(ddd,J=7.8,4.2,1.3Hz,1H),7.40(td,J=7.5,1.4Hz,1H),7.18(td,J=7.5,1.4Hz, 1H),7.02–6.85(m,7H),4.60(p,J=6.6Hz,1H),2.27(d,J=2.2Hz,12H),2.21(s,2H),1.31(d,J=6.5Hz,3H).
[0069] 13 C NMR (101MHz, CDCl3) δ151.32,151.10,146.26,145.95,135.29,133.65,132.61,1 32.52,130.12,128.35,128.21,127.75,126.18,125.35,58.62,26.52,23.21.
[0070] 31 P NMR (162MHz,CDCl3)δ-16.37.
[0071] HRMS(ESI) Calculate for [M+H,C 24 H 29 NP] + :362.20376,found:362.20363.
[0072] The synthesis method of the following compounds (IIb-IIc) is the same as that of Example 1, except that: (IIb) replaces di(3,5-dimethylphenyl)phosphine chloride with di(4-methoxyphenyl)phosphine chloride, and (IIc) replaces di(3,5-dimethylphenyl)phosphine chloride with di(3,5-di-tert-butylphenyl)phosphine chloride.
[0073] The structural formula of (S)-1-(2-bis(4-methoxyphenyl)phosphine)phenylethylamine (IIb) is:
[0074]
[0075] Yellow powder, yield 30%, [α] D 26 =65.2 (c 0.50, CHCl3), melting point 89-91°C.
[0076] 1 H NMR (400MHz, CDCl3) δ7.56(ddd,J=7.8,4.2,1.4Hz,1H),7.37–7.32(m,2H),7.23(dt,J=7.3,1.6Hz,3H),7.15(td, J=7.5,1.4Hz,1H),6.94–6.86(m,5H),4.50(p,J=6.6Hz,1H),3.82(s,6H),2.16(s,2H),1.21(d,J=6.5Hz,3H).
[0077] 13 C NMR (101MHz, CDCl3) δ149.68,149.36,140.96,139.56,139.23,138.99,138.36,1 37.25,136.21,135.62,132.21,129.26,124.23,118.26,58.56,53.15,24.71.
[0078] 31 P NMR (162MHz,CDCl3)δ-20.08.
[0079] HRMS(ESI)Calculate for [M+H,C 22 H 25 NO2P] + :366.16229,found:366.16221.
[0080] The structural formula of (S)-1-(2-bis(3,5-di-tert-butylphenyl)phosphine)phenylethylamine (IIc) is:
[0081]
[0082] Yellow powder, yield 18%, [α] D 26 =38.6 (c 0.50, CHCl3), melting point 111-114°C.
[0083] 1 H NMR (400MHz, CDCl3) δ7.54–7.43(m,1H),7.35(td,J=7.0,1.6Hz,1H),7.24(td,J=7.0,1.6Hz,1H),6 .92–6.67(m,7H),4.42(p,J=6.6Hz,1H),2.62(s,2H),2.08-1.92(m,36H),1.29(d,J=6.5Hz,3H).
[0084] 13 C NMR (101MHz, CDCl3) δ149.33,148.59,141.23,139.65,137.69,133.31,132.65,1 31.76,131.26,127.96,125.66,122.65,121.23,60.01,36.25,31.26,22.89.
[0085] 31 P NMR (162MHz,CDCl3)δ-16.22.
[0086] HRMS(ESI) Calculate for [M+H,C 36 H 53 NP] + :530.39156,found:530.39141.
[0087] Example 2: Preparation of Intermediates (S)-N-alkyl-1-(2-diarylphosphino)phenylethylamine IIIa-IIIe (S)-N-ethyl-1-(2-diphenylphosphino)phenylethylamine (IIIa)
[0088]
[0089] Add (S)-1-(2-diphenylphosphino)phenylethylamine (3.05g, 10mmol) and acetaldehyde (0.66g, 15mmol) to a 50mL Schlenck bottle and place the system under argon protection. Then add ultra-dry methanol (20mL) and stir at room temperature for 1h. Then pre-cool the system in an ice-water bath, quickly add sodium borohydride (1.14g, 30mmol), remove the ice-water bath, and react at room temperature for 3h. Monitor the reaction by TLC. After the reaction is completed, add water to quench the system at 0℃ and stirring. Add dichloromethane to the system until the two phases are clear, separate them with a separatory funnel, extract the aqueous phase with dichloromethane (50mL×3), combine the organic phases, wash the organic phases with saturated brine, and then dry them with anhydrous magnesium sulfate. Filter, concentrate the filtrate by rotary evaporation, and separate the crude product by silica gel column chromatography (eluent is petroleum ether / ethyl acetate = 2:1, v / v). Finally, 3.17 g of compound IIIa was obtained as a white viscous liquid with a yield of 95%. D 26 =51.2(c 0.50,CHCl3).
[0090] 1 H NMR (400MHz, CDCl3) δ7.47(ddd,J=7.9,4.3,1.4Hz,1H),7.27–7.12(m,11H),6.99(td,J=7.5,1.4Hz,1H),6.76(ddd,J=7.7,4 .3,1.4Hz,1H),4.53(p,J=6.6Hz,1H),2.37–2.14(m,2H),1.29–1.16(m,1H),1.11(d,J=6.5Hz,3H),0.80(t,J=7.1Hz,3H).
[0091] 13 C NMR (101MHz, CDCl3) δ150.49,150.27,137.29,137.19,136.93,136.82,135.22,135.09,134.28,134.11,134.09,133. 91,133.50,129.51,128.80,128.79,128.65,128.58,126.98,126.08,126.02,55.03,54.79,41.92,23.56,15.54.
[0092] 31 PNMR (162MHz,CDCl3)δ-17.03.
[0093] HRMS(ESI) Calculate for [M+H,C 22 H25 NP] + :334.17246,found:334.17251.
[0094] The synthesis method of the following compounds (IIIb-IIIe) is the same as that of Example 2, except that: R 1 The difference between (IIIc) and (IIIc) is that R 2 The phenyl group in (IIId) is replaced by 3,5-dimethylphenyl. 2 The phenyl group in (IIIe) is replaced by 4-methoxyphenyl. 2 The phenyl group is replaced by 3,5-di-tert-butylphenyl.
[0095] (S)-N-Benzyl-1-(2-diphenylphosphino)phenylethylamine (IIIb)
[0096]
[0097] White viscous liquid, yield 96%, [α] D 26 =52.9 (c 0.50, CHCl3).
[0098] 1 H NMR (400MHz, CDCl3) δ7.66–7.59(m,1H),7.35–7.02(m,17H),6.80(ddd,J=7.7,4.3,1.4H z,1H),4.65(p,J=6.6Hz,1H),3.44–3.28(m,2H),1.48(s,1H),1.16(d,J=6.4Hz,3H).
[0099] 13 C NMR (101MHz, CDCl3) δ150.18,140.69,137.20,137.09,136.85,136.75,135.28,135.15,134.25,134.05,133.87,133. 55,129.55,128.75,128.54,128.52,128.31,128.14,127.02,126.79,126.12,126.06,55.07,54.82,51.81,23.78.
[0100] 31 P NMR (162MHz,CDCl3)δ-17.38.
[0101] HRMS(ESI) Calculate for [M+H,C 27 H27 NP] + :396.18811,found:396.18765.
[0102] (S)-N-Methyl-1-(2-bis(3,5-dimethylphenyl)phosphinophenyl)ethylamine (IIIc)
[0103]
[0104] White viscous liquid, yield 87%, [α] D 26 =45.1(c 0.50,CHCl3).
[0105] 1 H NMR (400MHz, CDCl3) δ7.63(ddd,J=7.8,4.2,1.3Hz,1H),7.40(td,J=7.5,1.4Hz,1H),7.18(td,J=7.5,1.4Hz, 1H),7.02–6.85(m,7H),4.60(p,J=6.6Hz,1H),2.27(d,J=2.2Hz,12H),2.21(s,3H),1.31(d,J=6.5Hz,3H).
[0106] 13 C NMR (101MHz, CDCl3) δ150.36,143.13,142.36,140.22,138.66,138.33,137.98,136.23,134. 25,133.32,132.12,130.23,126.56,124.62,122.65,120.32,60.01,36.25,34.56,22.89.
[0107] 31 P NMR (162MHz,CDCl3)δ-16.24.
[0108] HRMS(ESI) Calculate for [M+H,C 25 H 31 NP] + :376.21941,found:76.21933.
[0109] (S)-N-Methyl-1-(2-bis(4-methoxyphenyl)phosphinophenyl)ethylamine (IIId)
[0110]
[0111] White viscous liquid, yield 85%, [α] D26 =66.3 (c 0.50, CHCl3).
[0112] 1 H NMR (400MHz, CDCl3) δ7.55(ddd,J=7.9,4.2,1.3Hz,1H),7.34(td,J=7.5,1.4Hz,1H),7.24–7.16(m,4H),7.15–7.10(m,1H),6. 97(ddd,J=8.8,6.0,2.3Hz,1H),6.92–6.86(m,4H),4.50(p,J=6.6Hz,1H),3.80(s,6H),2.14(s,3H),1.20(d,J=6.5Hz,3H).
[0113] 13 C NMR (101MHz, CDCl3) δ149.55,141.28,139.22,138.98,138.47,137.25,137.14,136.32,135. 87,134.36,134.06,131.59,130.15,129.01,123.31,117.22,59.63,55.63,35.22,25.29.
[0114] 31 P NMR (162MHz,CDCl3)δ-20.07.
[0115] HRMS(ESI) Calculate for [M+H,C 23 H 26 NO2P] + :379.17012,found:379.17019.
[0116] (S)-N-Methyl-1-(2-bis(3,5-di-tert-butylphenyl)phosphinophenyl)ethylamine(IIIe)
[0117]
[0118] White viscous liquid, yield 71%, [α] D 26 =40.3 (c 0.50, CHCl3).
[0119] 1 H NMR(400MHz, CDCl3)δ7.43–7.32(m,1H),7.28–7.24(m,2H),7.01–6.77(m,7H),4 .36(p,J=6.6Hz,1H),2.16(s,3H),2.08-1.92(m,36H),1.29(d,J=6.5Hz,3H).
[0120] 13 C NMR (101MHz, CDCl3) δ151.69,151.23,143.61141.26,137.12,135.36,133.65,132.76, 132.01,128.36,124.26,123.12,121.59,59.85,36.25,33.89,32.45,30.24,23.59.
[0121] 31 P NMR (162MHz,CDCl3)δ-16.88.
[0122] HRMS(ESI) Calculate for [M+H,C 37 H 55 NP] + :544.40721,found:544.40715.
[0123] Example 3: Preparation of Chiral Bisphosphine Ligands Ia-Ie
[0124] Chiral bisphosphine ligand Ia
[0125]
[0126] IIIa (1.56 g, 4.6 mmol), freshly evaporated toluene (30 mL) and freshly evaporated triethylamine (3.2 mL, 23 mmol) were added to a 100 mL three-necked flask in sequence. The system was frozen and degassed, and then placed under argon protection. The system was precooled in an ice-water bath, and then diphenylphosphine (1.3 mL, 6.9 mmol) was added dropwise. After the addition was completed, the ice-water bath was removed and the reaction was carried out at 120°C for 24 h. After TLC confirmed that the reaction was complete, the heating was stopped. After the system returned to room temperature, it was filtered through diatomaceous earth. The filtrate was vacuum-desolvated and the obtained crude product was separated by neutral alumina column chromatography (eluent: petroleum ether / ethyl acetate = 50:1, v / v), and finally 1.72 g of chiral bisphosphine ligand Ia was obtained as a white solid, with a yield of 79%, a melting point of 156-158°C (decomposition), [α] D 27 =49.5 (c 0.50, CHCl3).
[0127] 1 H NMR(400MHz, CDCl3) δ7.73(s,1H),7.51–7.20(m,21H),7.12(t,J=7.1Hz,1H),6.91(s,1H),5.31(q,J=16.4,12.5Hz ,1H),3.03(dd,J=13.0,6.5Hz,1H),2.88(dd,J=11.9,5.9Hz,1H),1.54(d,J=6.5Hz,3H),0.47(t,J=6.5Hz,3H).
[0128] 13 C NMR (101MHz, CDCl3) δ151.61,151.38,141.30,141.14,139.98,139.86,137.36,137.25,137.02,136.9 2,134.53,134.41,134.02,133.97,133.83,133.77,133.52,132.74,132.53,132.06,131.86,129.3 5,128.74,128.62,128.60,128.56,128.55,128.50,128.36,128.16,128.10,127.96,127.91,127.72,127.42,127.37,127.32,126.92,55.31,55.05,54.78,44.81,44.71,24.86,24.60,14.08,14.04.
[0129] 31 P NMR (162MHz, CDCl3) δ43.44 (d, J = 4.6Hz), -17.55 (d, J = 4.8Hz).
[0130] HRMS(ESI) Calculate for [M+H,C 34 H 34 NP2] + :518.21610,found:518.21613.
[0131] The synthesis method of the following chiral bisphosphine ligands (Ib-Ie) is the same as that of Example 3, except that: R 1 The difference between (Ic) and (Ic) is that R 2 The phenyl group in (Id) is replaced by 3,5-dimethylphenyl. 2 The phenyl group in (Ie) is replaced by 4-methoxyphenyl group. 2 The phenyl group is replaced by 3,5-di-tert-butylphenyl.
[0132] Chiral bisphosphine ligand Ib
[0133]
[0134] White solid, yield: 72%, melting point: 122-124℃ (decomposition), [α] D 27 =54.0 (c 0.50, CHCl3).
[0135] 1 H NMR (400MHz, CDCl3) δ7.89(d,J=4.5Hz,1H),7.56–7.47(m,2H),7.35–7.28(m,7H),7.23(dd,J=6.6,3.6Hz,10H),7.14–6.96(m, 6H), 6.90 (ddd, J=7.7, 4.0, 1.4Hz, 1H), 6.63 (d, J=7.0Hz, 2H), 5.17–5.06 (m, 1H), 4.33–4.16 (m, 2H), 1.46 (d, J=7.0Hz, 3H).
[0136] 13 C NMR (101MHz, CDCl3) δ150.82,150.57,141.14,140.99,140.27,140.14,139.49,137.55,137.43,135.26,13 5.12,134.22,134.07,134.02,133.87,133.79,133.75,133.56,131.94,131.75,129.51,129.13,128.9 5,128.88,128.79,128.71,128.68,128.61,128.58,128.51,128.43,128.10,128.05,127.94,127.86,127.81,127.78,127.73,127.20,126.37,56.10,55.86,55.83,55.60,54.34,54.25,54.23,24.50,24.28.
[0137] 31 P NMR (162MHz, CDCl3) δ45.18 (d, J = 4.8Hz), -17.57 (d, J = 5.1Hz).
[0138] HRMS(ESI) Calculate for [M+H,C 39 H 36 NP2] +:578.23230,found:580.23228.
[0139] Chiral bisphosphine ligand Ic
[0140]
[0141] White viscous liquid, yield: 42%, [α] D 26 =67.3 (c 0.50, CHCl3).
[0142] 1 H NMR (400MHz, CDCl3) δ7.56(dd,J=7.9,4.4Hz,1H),7.38(td,J=7.3,1.8Hz,2H),7.32–7.19(m,9H),7.12–7.04(m,1H) ,6.94–6.80(m,7H),5.16(h,J=7.2Hz,1H),2.28(d,J=2.6Hz,3H),2.17(d,J=11.7Hz,12H),1.50(d,J=6.8Hz,3H).
[0143] 13 C NMR (101MHz, CDCl3)δ150.23,150.18,150.00,149.96,140.45,140.28,139.77,139.63,137.92,13 7.89,137.85,137.82,137.12,137.01,136.95,136.85,135.74,135.60,133.87,132.91,132.70 ,132.03,131.95,131.84,131.78,131.76,131.58,130.54,130.48,129.02,128.29,128.14,128.10,128.05,127.98,127.05,126.63,60.36,60.11,60.08,36.12,36.00,23.03,22.81,21.44.
[0144] 31 P NMR (162MHz, CDCl3) δ49.11 (d, J = 9.1Hz), -17.00 (d, J = 9.6Hz).
[0145] HRMS(ESI) Calculate for [M+H,C 37 H 40 NP2] + :560.26271,found:560.26263.
[0146] Chiral bisphosphine ligand Id
[0147]
[0148] White viscous liquid, yield: 44%, [α] D 27 =45.9 (c 0.50, CHCl3).
[0149] 1 H NMR (400MHz, CDCl3) δ7.48 (dd, J=7.8, 4.4Hz, 1H), 7.31 (dt, J=7.0, 3.6Hz, 2H), 7.19 (qd, J=8.3, 3.8Hz, 9H), 7.11–6.98 (m, 5 H), 6.74 (dd, J = 11.8, 8.3Hz, 5H), 5.09 (h, J = 7.2Hz, 1H), 3.65 (d, J = 6.5Hz, 6H), 2.19 (d, J = 2.6Hz, 3H), 1.39 (d, J = 6.9Hz, 3H).
[0150] 13 C NMR (101MHz, CDCl3) δ160.22,160.19,149.81,149.76,149.59,149.54,140.32,140.16,139.67,139.53,1 36.48,136.33,135.63,135.54,135.42,135.33,133.27,132.85,132.64,131.97,131.78,128.88,128. 27,128.22,128.17,128.07,128.05,128.01,127.94,126.96,126.77,126.75,126.73,126.70,114.33,114.29,114.25,114.21,60.15,59.91,59.62,55.20,36.01,36.00,35.91,35.90,27.00,22.84,22.62.
[0151] 31 P NMR (162MHz, CDCl3) δ49.23 (d, J = 9.5Hz), -20.61 (d, J = 9.6Hz).
[0152] HRMS(ESI) Calculate for [M+H,C 35 H 36 NO2P2] +:564.22101,found:564.22089.
[0153] Chiral bisphosphine ligand Ie
[0154]
[0155] White viscous liquid, yield: 36%, [α] D 27 =55.3 (c 0.50, CHCl3).
[0156] 1 H NMR (400MHz, CDCl3) δ7.57–7.50(m,5H),7.47–7.36(m,6H),7.36–7.25(m,9H),4.96(h,J=6.6Hz,1H),2.38(s,3H),1.41(s,3H),1.28(s,36H).
[0157] 13 C NMR (101MHz, CDCl3) δ144.74,144.21,143.65,140.14,138.74,137.32,137.1 2,134.71,132.98,130.21,129.97,129.39,129.04,128.27,127.44,126. 31,124.08,123.65,61.41,60.56,59.81,59.72,54.25,42.65,42.34,40. 56,40.12,39.72,36.56,36.01,36.00,35.91,35.90,34.99,31.41,18.76.
[0158] 31 P NMR (162MHz, CDCl3) δ49.23 (d, J = 9.5Hz), -20.61 (d, J = 9.6Hz).
[0159] HRMS(ESI) Calculate for [M+H,C 49 H 64 NP2] + :728.45140,found:728.45139.
[0160] Example 4: Preparation of Chiral Bisphosphine Ligand Rhodium Complexes IVa-IVd
[0161] Chiral Bisphosphine Ligand Rhodium Complex IVa
[0162]
[0163] In a glove box, ligand Ia (103 mg, 0.20 mmol), [Rh(COD)Cl]2 (49 mg, 0.10 mmol), NaBAr F ·1.3H2O (200 mg, 0.24 mmol), then seal it and take it out of the glove box, and keep the system in argon atmosphere, then add ultra-dry dichloromethane (2 mL) with a syringe, stir and complex at room temperature for 3 hours, TLC confirms that the reaction is complete, and stop the reaction. After vacuum desolventizing, the reaction solution is purified by silica gel column chromatography (eluent is petroleum ether / ethyl acetate = 5:1, v / v) to obtain the target product containing BAr F - Anionic chiral diphosphine ligand rhodium complex IVa 221 mg, brown-yellow solid, yield: 71%, melting point: 85-89°C (decomposition), [α] D 25 =66(c 0.50,CHCl3).
[0164] 1 H NMR (400MHz, CDCl3) δ7.98–7.86(m,2H),7.77(s,8H),7.60–7.40(m,16H),7.24(ddt,J=29.3,22.0,7.4Hz ,7H),6.90(dt,J=29.8,9.0Hz,3H),6.32(t,J=9.1Hz,2H),5.83(dt,J=23.7,6.8Hz,2H),4.40–4.26(m, 1H),3.94(d,J=7.6Hz,1H),3.78(t,J=6.5Hz,1H),3.22(dp,J=13.3,6.6Hz,1H),2.86(dq,J=16.1,8.2 Hz,2H),2.47(dd,J=16.7,8.0Hz,1H),2.28–2.06(m,4H),1.35(d,J=7.1Hz,3H),0.65(t,J=6.9Hz,3H).
[0165] 13 C NMR(101MHz, CDCl3) δ162.53,162.04,161.54,161.05,144.52,144.39,136.1 3,136.00,134.87,133.01,132.97,131.99,131.89,131.84,131.82,131. 65,131.55,131.29,131.27,131.15,130.94,130.92,130.86,130.81,130 .70,130.49,130.37,129.95,129.46,129.32,129.21,129.14,129.01,12 8.91,128.79,128.67,128.51,128.27,127.85,127.79,127.71,125.96,125.69,125.61,123.25,120.54,117.53,117.48,108.90,108.83,97.06,9 7.00,96.86,96.52,94.45,94.33,94.25,58.97,58.80,58.63,53.42,40.39,40.33,34.13,32.72,32.68,29.74,28.37,27.09,18.69,18.58,17.41.
[0166] 31 P NMR (162MHz, CDCl3) δ88.82 (dd, J = 152.9, 32.6Hz), 17.49 (dd, J = 149.0, 32.7Hz);
[0167] HRMS(ESI) Calculate for [positive ion, C 42 H 45 NP2Rh] + :728.20822,found728.20691.
[0168] The preparation method of the chiral bisphosphine ligand rhodium complex IVb is the same as that of the chiral bisphosphine ligand rhodium complex IVa, except that Ia is replaced by Ib.
[0169]
[0170] Brown-yellow solid, yield: 58%, melting point: 96-98°C (decomposition), [α] D 25 =96(c 0.50,CHCl3).
[0171] 1 H NMR(400MHz,CDCl3)δ7.97(ddd,J=10.4,6.7,3.0Hz,2H),7.87–7.81(m,8H),7.67–6.80(m,31H),6.51(dd,J=10.6,7.6Hz,2H),6.14(m,1H),6.01(d,J=7.8Hz,1H),4.53–4.32(m,2H),4.22(dd,J=16.7,8.2Hz,1H),4.05(dd,J=17.7,9.8Hz,2H),2.92(dq,J=16.4,9.0Hz,1H),2.54(dd,J=16.7,7.8Hz,1H),2.37–2.08(m,4H),1.10(d,J=7.1Hz,3H)。
[0172] 13 C NMR (101MHz,CDCl3)δ166.18,161.23,160.53,153.20,152.83,152.58,152.58,147.92,146.06,144.10,143.15,143.00,142.27,142.15,141.50,139.56,139.44,137.27,137.13,136.23,136.07,136.03,135.88,135.80,135.76,135.57,133.95,133.76,132.77,131.52,131.14,130.96,130.89,130.79,130.72,130.68,130.62,130.59,130.52,130.43,130.11,130.06,129.95,129.87,129.81,129.79,129.74,129.21,128.38,128.28,125.75,124.66,121.76,121.42,116.98,115.55,113.60,111.15,109.41,106.86,98.30,94.97,92.29,71.08,64.82,62.65,58.11,58.11,57.87,57.84,57.60,56.35,56.26,56.24,50.52,42.03,32.89,26.51,26.51,26.29,15.71.
[0173] 31 P NMR (162MHz,CDCl3)δ90.23(dd,J=155.0,30.8Hz),17.00(dd,J=148.2,30.8Hz).
[0174] HRMS(ESI) Calculate for [positive ion, C 47 H 47 NP2Rh] + :790.22393,found790.22245.
[0175] The preparation method of the chiral bisphosphine ligand rhodium complex IVc is the same as that of the chiral bisphosphine ligand rhodium complex IVa, except that Ia is replaced by Ic.
[0176]
[0177] Brown-yellow solid, yield: 75%, melting point: 67-70°C (decomposition), [α] D 25 =84(c 0.50,CHCl3).
[0178] 1 H NMR (400MHz, CDCl3) δ7.64(d,J=4.7Hz,9H),7.44–7.25(m,15H),7.16(t,J=7.8Hz,2H),7.01(d,J=8.7Hz ,2H),6.94–6.74(m,4H),5.87(d,J=11.0Hz,2H),5.76(dt,J=11.9,6.0Hz,1H),5.38(t,J=7.3Hz,1H), 4.27(t,J=7.7Hz,1H),3.91(d,J=8.2Hz,1H),3.72–3.61(m,1H),2.75(dq,J=17.0,9.0Hz,1H),2.41–2 .35(m,1H),2.30(d,J=6.8Hz,3H),2.16(s,6H),2.16–1.89(m,4H),2.01(s,6H),1.23(d,J=6.9Hz,3H)
[0179] 13 C NMR(101MHz, CDCl3) δ162.56,162.06,161.57,161.07,143.84,143.72,138.99,138.88,138.76,134.89,133.75,133.63 ,133.52,133.16,132.67,131.48,131.10,130.94,130.84,130.35,130.23,129.51,129.41,129.21,129.11,128.80, 128.70,127.74,127.57,127.50,125.98,125.00,124.92,123.27,120.57,117.51,109.90,97.87,97.68,95.57,92.49,60.38,58.09,57.92,57.74,34.46,34.42,33.20,30.76,30.71,27.96,26.82,21.15,21.08,15.42,15.33,14.07.
[0180] 31 P NMR (162MHz, CDCl3) δ89.07 (dd, J=154.1, 32.9Hz), 16.91 (dd, J=147.5, 33.1Hz).
[0181] HRMS(ESI) Calculate for [positive ion, C 45 H 51 NP2Rh] + :770.25460,found770.25416.
[0182] The preparation method of the chiral bisphosphine ligand rhodium complex IVd is the same as that of the chiral bisphosphine ligand rhodium complex IVa, except that Ia is replaced by Id.
[0183]
[0184] Brown-yellow solid, yield: 68%, melting point: 62-65°C (decomposition), [α] D 25 =54(c 0.50,CHCl3).
[0185] 1 H NMR(400MHz,CDCl3)δ7.73(s,8H),7.53(s,4H),7.44(d,J=9.9Hz,10H),7.31–7.24(m,3H),7.13(t,J=7.5Hz,1H),7.06–6.95(m,4H),6.81(dd,J=27.9,8.6Hz,3H),6.32(t,J=9.3Hz,2H),5.85(dt,J=11.9,6.0Hz,1H),5.45(d,J=7.4Hz,1H),4.35(q,J=9.7Hz,1H),4.12(s,1H),3.79(d,J=16.9Hz,7H),2.79(dq,J=16.7,8.7Hz,1H),2.42(d,J=6.8Hz,3H),2.14(m,5H),1.37(d,J=6.9Hz,3H)
[0186] 13 C NMR (101MHz,CDCl3)δ162.49,162.20,161.99,161.49,161.00,137.54,137.40,134.83,133.59,133.47,132.67,132.37,131.56,130.95,130.78,130.68,130.29,130.17,129.26,129.15,128.78,127.71,127.57,125.93,123.22,121.64,120.51,118.94,118.46,117.48,114.92,114.81,114.70,114.59,97.56,95.83,93.17,57.71,55.37,55.26,53.42,34.16,33.00,32.96,30.83,30.78,28.25,26.96,15.70,15.60.
[0187] 31 P NMR (162MHz,CDCl3)δ88.52(dd,J=154.3,33.1Hz),14.20(dd,J=147.5,33.3Hz).
[0188] HRMS(ESI) calcd for[positive ion,C 43 H 47 NO2P2Rh] + :774.21323,found774.21251.
[0189] Example 5: Study on the Asymmetric Hydrogenation of Z-3-Acetylaminobutenoic Acid Ethyl Ester Using Catalysts IVa-IVd
[0190]
[0191] In a glove box, catalyst IVa (3.6 mg, 2.3 μmol, 1.0 mol%), IVb (3.8 mg, 2.3 μmol, 1.0 mol%), IVc (3.7 mg, 2.3 μmol, 1.0 mol%), and IVd (3.7 mg, 2.3 μmol, 1.0 mol%) were added to four hydrogenation inner tubes, and then Z-3-acetylaminobutenoic acid ethyl ester (40 mg, 0.23 mmol) was added to each hydrogenation inner tube, sealed with a sealing film, taken out of the glove box, and placed in a hydrogenation kettle, and freshly distilled degassed ethanol (1 mL) was quickly added. After stirring evenly, the hydrogenation kettle was tightened, hydrogen was quickly replaced 3 times, and hydrogen (25 atm) was filled. The reaction was stirred at room temperature (rt) for 12 h. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, dibromomethane was added as an internal standard, and the conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluent EA) and then the ee value was determined by HPLC (AD-3, n-hexane / isopropanol=92:8; 1.0 mL / min, 210 nm). The reaction results are shown in Table 1, and the results show that catalyst IVc has the best catalytic performance in the asymmetric hydrogenation reaction of β-dehydroamino acid esters.
[0192] Table 1: Experimental results of asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate using different catalysts
[0193]
[0194] a 1 H NMR quantitative (internal standard CH2Br2)
[0195] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0196] Example 6: Effect of anions on the asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate
[0197]
[0198] In a glove box, ligand Ic (2.8 mg, 5 μmol, 1.1 mol%), [Rh(COD)Cl]2 (1.0 mg, 2.3 μmol, 0.5 mol%), and ethyl Z-3-acetylaminobutenoate (80 mg, 0.47 mmol) were added to five hydrogenation inner tubes, followed by AgBF4 (1.0 mg, 5 μmol, 1.1 mol%), AgPF6 (1.3 mg, 5 μmol , 1.1mol%), AgSbF4 (1.7mg, 5μmol, 1.1mol%), and AgOTf (1.3mg, 5μmol, 1.1mol%) were added to four hydrogenation inner tubes respectively, sealed with sealing film, taken out of the glove box, and placed in the hydrogenation kettle, and freshly distilled degassed ethanol (2mL) was quickly added, and the hydrogenation kettle was tightened after stirring evenly, and the hydrogen was quickly replaced 3 times, and hydrogen (25atm) was filled. The reaction was stirred at room temperature for 12h. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, and dibromomethane was added as an internal standard. The conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluent EA) and the ee value was determined by HPLC (AD-3, n-hexane / isopropanol = 92:8; 1.0mL / min, 210nm). The reaction results are shown in Table 2.
[0199] Table 2: Experimental results of asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate using different catalysts
[0200]
[0201] a1 H NMR quantitative (internal standard CH2Br2)
[0202] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0203] c The same experimental conditions, the amount of substrate increased to: 400mg, 2.3mmol.
[0204] d Catalyst IVc (3.6 mg, 2.3 μmol, 0.2 mol%), Z-3-acetylaminobutenoic acid ethyl ester (200 mg, 1.15 mmol)
[0205] Example 7: Effect of Hydrogen Pressure on Asymmetric Hydrogenation of Ethyl Z-3-Acetylaminobutenoate
[0206]
[0207] In the glove box, Z-3-acetylaminobutenoic acid ethyl ester (40 mg, 0.23 mmol) and the corresponding amount of catalyst IVc (3.7 mg, 2.3 μmol, 1.0 mol%) were weighed into the hydrogenation inner tube in sequence, sealed with a sealing film, taken out of the glove box, and placed in the hydrogenation kettle, and freshly distilled degassed ethanol (2 mL) was quickly added. After stirring evenly, the hydrogenation kettle was tightened, and hydrogen was quickly replaced 3 times, and hydrogen at different pressures was filled. The reaction was stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, dibromomethane was added as an internal standard, and the conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluent EA) and then the ee value was determined by HPLC.
[0208] Table 3: Experimental results of hydrogen pressure on asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate
[0209]
[0210] a 1 H NMR quantitative (internal standard CH2Br2)
[0211] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0212] Example 8: Effect of Temperature on Asymmetric Hydrogenation of Ethyl Z-3-Acetylaminobutenoate
[0213]
[0214] In the glove box, Z-3-acetylaminobutenoic acid ethyl ester (40 mg, 0.23 mmol) and catalyst IVc (3.7 mg, 2.3 μmol, 1.0 mol%) were weighed into the hydrogenation inner tube in sequence, sealed with a sealing film, taken out of the glove box, and placed in the hydrogenation kettle, and freshly distilled degassed ethanol (2 mL) was quickly added. After stirring evenly, the hydrogenation kettle was tightened, and hydrogen was quickly replaced 3 times, and hydrogen (30 atm) was filled. The reaction was stirred for 12 hours under different temperature conditions. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, dibromomethane was added as an internal standard, and the conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluent EA) and then the ee value was determined by HPLC.
[0215] Table 4: Experimental results of asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate at different temperatures
[0216]
[0217] a 1 H NMR quantitative (internal standard CH2Br2)
[0218] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0219] Example 9: Effect of Catalyst Amount on Asymmetric Hydrogenation of Ethyl Z-3-Acetylaminobutenoate
[0220]
[0221] In the glove box, catalyst IVc (3.7 mg, 2.3 μmol, 1.0 mol%) and the corresponding amount of Z-3-acetylaminobutenoic acid ethyl ester were weighed into the hydrogenation inner tube in sequence, sealed with a sealing film, taken out of the glove box, and placed in the hydrogenation kettle, and freshly distilled degassed ethanol (2-5 mL) was quickly added. After stirring evenly, the hydrogenation kettle was tightened, and hydrogen was quickly replaced 3 times, and hydrogen (30 atm) was filled. The reaction was stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, and dibromomethane was added as an internal standard. The conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluting liquid EA) and then the ee value was determined by HPLC. The experimental results show that the conversion number can reach up to 4400, and the ee value is 70% at this time.
[0222] Table 5: Experimental results of catalyst dosage for asymmetric hydrogenation of ethyl Z-3-acetylaminobutenoate
[0223]
[0224] a 1 H NMR quantitative (internal standard CH2Br2)
[0225] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0226] c Response time: 48h
[0227] Example 10: Study on the Applicability of Substrates for Asymmetric Hydrogenation of β-Dehydroamino Acid Esters
[0228]
[0229] In the glove box, catalyst IVc (3.7 mg, 2.3 μmol, 1.0 mol%) and the corresponding amount of β-dehydroamino acid ester substrate were weighed into the hydrogenation inner tube in sequence, sealed with a sealing film, taken out of the glove box, and placed in the hydrogenation kettle, and freshly distilled degassed ethanol (2 mL) was quickly added. After stirring evenly, the hydrogenation kettle was tightened, and hydrogen was quickly replaced 3 times, and hydrogen (30 atm) was filled. The reaction was stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was transferred to a round-bottom flask, the solvent was removed by rotary evaporation, and dibromomethane was added as an internal standard. The conversion rate and yield were determined by nuclear magnetic resonance. The remaining crude product was passed through a short silica gel column (eluent EA) and then the ee value was determined by HPLC.
[0230] Table 6: Experimental results of the study on the scope of substrate applicability for asymmetric hydrogenation of β-dehydroamino acid esters
[0231]
[0232] a 1 H NMR quantitative (internal standard CH2Br2)
[0233] b HPLC: chiral column AD-3, n-hexane / isopropanol = 92:8, 1.0 mL / min, 210 nm.
[0234] The above description is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several modifications and improvements without departing from the inventive concept, which all belong to the protection scope of the present invention.
Claims
1. Use of a chiral bisphosphine ligand rhodium complex as a catalyst in the asymmetric hydrogenation reaction of β-dehydrogenated amino acid esters, It is characterized in that The chiral diphosphine ligand rhodium complex is:
